Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults
Conditions
Interventions
VCL-HB01
VCL-HM01
+1 more
Locations
7
United States
Alabama Vaccine Research Clinic
Birmingham, Alabama, United States
Broward Research Group
Hollywood, Florida, United States
Indiana University Infectious Diseases Research
Indianapolis, Indiana, United States
Westover Heights Clinic
Portland, Oregon, United States
Center for Clinical Studies
Houston, Texas, United States
University of Utah - Division of Infectious Diseases
Salt Lake City, Utah, United States
Start Date
December 1, 2013
Primary Completion Date
June 1, 2015
Completion Date
February 1, 2016
Last Updated
February 27, 2019
NCT05432583
NCT06698575
NCT02114060
NCT02300142
Lead Sponsor
Vical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions